Notice ID: 883cad98d13c4a1386c91d9184c8f1f2Combined Synopsis/Solicitation
Human primary CD34+ Hematopoietic stem and Progenitor cells
Archived on September 16, 2020. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM UTC−05:00
- Posted
- August 18, 2020
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION
Notice details
- Office
- FDA OFFICE OF ACQ GRANT SVCS
- Place of performance
- Silver Spring, MD, 20993
- Last updated
- Apr 29, 2026
Identifiers
- Solicitation number
- FDA-SOL-1233197
- Notice ID
- 883cad98d13c4a1386c91d9184c8f1f2
Description
The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) / Division of Cell and Gene Therapy (DCGT), Office of Cellular, Tissue and Gene Therapy requires Human primary CD34+ hematopoietic stem and progenitor cells to have assessed identity and characterization of gene and cell therapy products to perform critical path research for its mission to develop and promote technology to regulate cellular and genetic therapeutics.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
FDA-SOL-1233197- Combined Synopsis
- Combined SynopsisCurrentAug 18, 2020
Human primary CD34+ Hematopoietic stem and Progenitor cells
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
FDA-SOL-1233197
Archive Date
Sep 16, 2020
Office Address
Beltsville, MD, 20705